{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:19:45Z","timestamp":1791724785761,"version":"4.3.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Galanin is a neuropeptide in the central nervous system that regulates mood and alcohol consumption. Its N-terminal fragment, Galanin (1\u201315) [GAL (1\u201315)], has demonstrated specific behavioral effects, enhancing the efficacy of selective serotonin reuptake inhibitors (SSRIs) and reducing ethanol intake and alcohol self-administration in preclinical models. Additionally, GAL (1\u201315) combined with SSRIs decreases alcohol self-administration and depressive symptoms in a comorbid alcoholism-depression model. These findings suggest potential applications in the treatment of depression and alcohol use disorders. Given its therapeutic potential, evaluating the translational aspects and safety of GAL (1\u201315) is essential for clinical development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study investigated the intranasal administration of GAL (1\u201315), assessing its effects on depression-related behavior in the Forced Swim Test (FST) and alcohol self-administraation in an operant selfadministration model. To determine its safety profile, we evaluated GAL (1\u201315) for cardio toxicity (hERG channel inhibition), genotoxicity (micronucleus formation), and drug interactions (CYP450 inhibition).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results showed that intranasal GAL (1\u201315) exhibited a prodepressant effect, as previously demonstrated with its ICV administration. Furthermore, intranasal GAL (1\u201315) effectively reduced alcohol consumption. In vitro safety assessments revealed no adverse effects on cardiac function or genotoxicity at the concentrations studied, with minimal interaction with CYP450 enzymes, supporting its suitability for drug development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In conclusion, intranasal administration of GAL (1\u201315) represents a promising candidate for clinical trials due to its favorable safety profile and therapeutic potential. Its use appears particularly suitable as a standalone treatment for alcohol use disorder and, when combined with SSRIs, as a potential therapy for depressive disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1719440","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:34:54Z","timestamp":1764138894000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Intranasal Galanin (1\u201315) modulates alcohol self-administration and depressive-like behavior in rats and shows a favorable safety profile"],"prefix":"10.3389","volume":"16","author":[{"given":"Noelia","family":"Cantero-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Flores-Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Flores-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pedro","family":"Pineda-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caridad","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Mill\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaida","family":"D\u00edaz-Cabiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12936-021-03993-8","article-title":"Preclinical evaluation of strasseriolides A-D, potent antiplasmodial macrolides isolated from Strasseria geniculata CF-247,251","volume":"20","author":"Annang","year":"2021","journal-title":"Malar. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nn849","article-title":"Sniffing neuropeptides: a transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bbrc.2014.08.061","article-title":"Preferential activation by galanin 1-15 fragment of the GalR1 protomer of a GalR1-GalR2 heteroreceptor complex","volume":"452","author":"Borroto-Escuela","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/s0165-6147(00)01446-2","article-title":"Galanin receptor subtypes","volume":"21","author":"Branchek","year":"2000","journal-title":"Trends Pharmacol. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"113508","DOI":"10.1016\/j.biopha.2022.113508","article-title":"Galanin N-terminal fragment (1-15) reduces alcohol seeking and alcohol relapse in rats: involvement of mesocorticolimbic system","volume":"153","author":"Cantero-Garc\u00eda","year":"","journal-title":"Biomed. Pharmacother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/biomedicines10020412","article-title":"The combination of galanin (1-15) and escitalopram in rats suggests a new strategy for alcohol use disorder comorbidity with depression","volume":"10","author":"Cantero-Garc\u00eda","year":"","journal-title":"Biomedicines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1021\/acs.jmedchem.2c01597","article-title":"Discovery and hit-to-lead optimization of benzothiazole scaffold-based DNA gyrase inhibitors with potent activity against Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"66","author":"Cotman","year":"2023","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1124\/jpet.108.145565","article-title":"Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system","volume":"328","author":"Dhuria","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.npep.2004.12.009","article-title":"Role of galanin and galanin(1-15) on central cardiovascular control","volume":"39","author":"D\u00edaz-Cabiale","year":"2005","journal-title":"Neuropeptides"},{"key":"B11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.regpep.2010.04.014","article-title":"The Galanin N-terminal fragment (1-15) interacts with neuropeptide Y in central cardiovascular control: involvement of the NPY Y2 receptor subtype","volume":"163","author":"D\u00edaz-Cabiale","year":"2010","journal-title":"Regul. Pept."},{"key":"B12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0378-5173(03)00039-5","article-title":"Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats","volume":"255","author":"Dufes","year":"2003","journal-title":"Int. J. Pharm."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1021\/acs.jmedchem.2c01905","article-title":"New dual inhibitors of bacterial topoisomerases with broad-spectrum antibacterial activity and in vivo efficacy against Vancomycin-intermediate Staphylococcus aureus","volume":"66","author":"Durcik","year":"2023","journal-title":"J. Med. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.peptides.2015.07.007","article-title":"The regulative effect of galanin family members on link of energy metabolism and reproduction","volume":"71","author":"Fang","year":"2015","journal-title":"Peptides"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1588902","DOI":"10.3389\/fpsyt.2025.1588902","article-title":"Editorial: treatment resistant depression (TRD): epidemiology, clinic, burden and treatment","volume":"16","author":"Fiorillo","year":"2025","journal-title":"Front. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuropharm.2017.03.010","article-title":"Galanin (1-15) enhancement of the behavioral effects of fluoxetine in the forced swimming test gives a new therapeutic strategy against depression","volume":"118","author":"Flores-Burgess","year":"2017","journal-title":"Neuropharmacology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neuropharm.2019.05.023","article-title":"Galanin (1-15)-fluoxetine interaction in the novel object recognition test. Involvement of 5-HT1A receptors in the prefrontal cortex of the rats","volume":"155","author":"Flores-Burgess","year":"2019","journal-title":"Neuropharmacology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/ijnp\/pyab089","article-title":"Galanin (1-15) enhances the behavioral effects of fluoxetine in the olfactory bulbectomy rat, suggesting a new augmentation strategy in depression","volume":"25","author":"Flores-Burgess","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1124\/dmd.121.000563","article-title":"Addressing today's absorption, distribution, metabolism, and excretion (ADME) challenges in the translation of in vitro ADME characteristics to humans: a case study of the SMN2 mRNA splicing modifier risdiplam","volume":"50","author":"Fowler","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"B20","doi-asserted-by":"publisher","first-page":"10848","DOI":"10.3390\/ijms221910848","article-title":"Galanin(1-15) potentiates the antidepressant-like effects induced by escitalopram in a rat model of depression","volume":"22","author":"Garc\u00eda-Dur\u00e1n","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.npep.2017.03.005","article-title":"Short N-terminal galanin fragments are occurring naturally in vivo","volume":"63","author":"Ihnatko","year":"2017","journal-title":"Neuropeptides"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/npp.2011.317","article-title":"Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons","volume":"37","author":"Ionescu","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.peptides.2004.02.015","article-title":"Galanin in the brain: chemoarchitectonics and brain cartography--a historical review","volume":"25","author":"Jacobowitz","year":"2004","journal-title":"Peptides"},{"key":"B25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pharmthera.2007.05.009","article-title":"The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease","volume":"115","author":"Lang","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/adb.12521","article-title":"Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration","volume":"23","author":"Lebourgeois","year":"2018","journal-title":"Addict. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12859-019-2814-5","article-title":"Computational determination of hERG-related cardiotoxicity of drug candidates","volume":"20","author":"Lee","year":"2019","journal-title":"BMC Bioinforma."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1523\/JNEUROSCI.06-12-03640.1986","article-title":"Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS","volume":"6","author":"Melander","year":"1986","journal-title":"J. Neurosci."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu064","article-title":"A role for galanin N-terminal fragment (1-15) in anxiety- and depression-related behaviors in rats","volume":"18","author":"Mill\u00f3n","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1007\/s00429-015-1180-y","article-title":"Galanin (1-15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system","volume":"221","author":"Mill\u00f3n","year":"2016","journal-title":"Brain Struct. Funct."},{"key":"B31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1177\/0269881119844188","article-title":"Role of the galanin N-terminal fragment (1-15) in anhedonia: involvement of the dopaminergic mesolimbic system","volume":"33","author":"Mill\u00f3n","year":"","journal-title":"J. Psychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/adb.12582","article-title":"Central administration of galanin N-terminal fragment 1-15 decreases the voluntary alcohol intake in rats","volume":"24","author":"Mill\u00f3n","year":"","journal-title":"Addict. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-3-0346-0228-0_2","article-title":"Galanin, galanin receptors and drug targets","volume":"65","author":"Mitsukawa","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/cimb47010007","article-title":"Advanced in vitro models for preclinical drug safety: recent progress and prospects","volume":"47","author":"Nair","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"B35","volume-title":"OECD guideline for the testing of chemicals: test guideline 487 \u2013 in vitro mammalian cell micronucleus test","year":"2016"},{"key":"B36","doi-asserted-by":"publisher","first-page":"111191","DOI":"10.1016\/j.pnpbp.2024.111191","article-title":"A new pharmacological strategy against treatment-resistant depression","volume":"136","author":"Pineda-G\u00f3mez","year":"2025","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.neuroscience.2013.01.040","article-title":"Single intranasal neuropeptide Y infusion attenuates development of PTSD-Like symptoms to traumatic stress in rats","volume":"236","author":"Serova","year":"2013","journal-title":"Neuroscience"},{"key":"B38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.euroneuro.2013.11.007","article-title":"Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model","volume":"24","author":"Serova","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.euroneuro.2019.02.010","article-title":"Single prolonged stress PTSD model triggers progressive severity of anxiety, altered gene expression in locus coeruleus and hypothalamus and effected sensitivity to NPY","volume":"29","author":"Serova","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0196-9781(85)90118-4","article-title":"Immunohistochemical mapping of galanin-like neurons in the rat central nervous system","volume":"6","author":"Skofitsch","year":"1985","journal-title":"Peptides"},{"key":"B41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/0014-5793(83)80033-7","article-title":"Galanin - a novel biologically active peptide from porcine intestine","volume":"164","author":"Tatemoto","year":"1983","journal-title":"FEBS Lett."},{"key":"B42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/0006-8993(95)00637-6","article-title":"Quantitative analysis of the olfactory pathway for drug delivery to the brain","volume":"692","author":"Thorne","year":"1995","journal-title":"Brain Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.neuroscience.2004.05.029","article-title":"Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration","volume":"127","author":"Thorne","year":"2004","journal-title":"Neuroscience"},{"key":"B44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0301-4622(95)00104-2","article-title":"Fluorescence and Monte Carlo conformational studies of the (1-15) galanin amide fragment","volume":"58","author":"Wiczk","year":"1996","journal-title":"Biophys. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1719440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:34:55Z","timestamp":1764138895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1719440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":44,"alternative-id":["10.3389\/fphar.2025.1719440"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1719440","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1719440"}}